FemiClear Bacterial Vaginosis (BV) Symptoms product

Bacterial vaginosis (BV) is a bacterial infection caused by the overgrowth of bacteria in the vagina. It’s very common — in fact, it’s estimated that up to 1 in 3 women will have BV in their lifetime. This infection is also likely to recur, as research indicates that around 50% of women who have a BV infection will have a recurrent case of BV within six (6) months of their initial diagnosis.

Researchers do not currently know the exact causative mechanism that results in BV; however, it is highly correlated to sexual activity and the bacterium Gardnerella vaginalis. Other potential related bacteria include Lactobacillus, Prevotella, and Streptococcus viridans among others3. 

Common symptoms of BV include a fishy odor, elevated vaginal pH, itching, burning while urinating and a thin, greyish/white discharge. Traditional remedies for BV include oral antibiotics, antibiotic suppositories, or boric acid suppositories.

Given the prevalence and recurrent nature of BV, as well as the risk of antibiotic resistance, additional treatment options outside of oral antibiotics and antibiotic suppositories are important in the management and treatment of BV infections. 

FemiClear® BV in Vitro Testing

A new over-the-counter product recently developed for BV infections was evaluated in vitro by an accredited laboratory according to the ASTM E2315 time-kill method. The test method allows a standardized and controlled method to compare the time-kill kinetics of various products to Gardnerella vaginalis. The reduction in G. vaginalis over a fixed time can be attributed to the test sample, and a resulting percent reduction was calculated. 

The new FemiClear BV product was tested for percent reduction of G. vaginalis in a four-hour time-kill study and resulted in a 99.99% reduction in G. vaginalis. 

FemiClear® BV in Vivo Testing

The same FemiClear Bacterial Vaginosis (BV) Symptoms product was tested in more than 100 participants in the USA over the course of 2 –10 days starting in March 2022. Each participant (who had an active BV infection when they used the product) completed an online self-assessment evaluation survey**.

During the study, the following were observed: 

• 95% of participants reported the product effectively treated their BV infection 
• 94% of participants reported elimination of fishy odor 
• 93% of participants reported elimination of grayish/white discharge 
• 94% of participants reported significantly reduced symptoms within 2 days of beginning use of the product 
• 83% of participants reported symptom relief within 24 hours of beginning use of the product 
• 82% of participants reported their infection was shorter than normal 
• 97% of participants reported liking the consistency and texture of the product 
• 90% of participants reported that they would recommend using the product 

It is reported in medical literature that 50% of women report a recurrence of BV infection within six (6) months.4 In this study, the vast majority of participants – 86% - are women who report experiencing recurrence of BV infection at least every 6 months. The breakdown of their reported infection frequency is as follows: 

A follow-up survey was conducted six (6) months after subjects had used the FemiClear BV product to find out how many had another BV infection since using it. The following results were collected: 

• 65 participants responded to this survey 
• 29.2% reported having another BV infection since using FemiClear 
• 70.8% reported having not had another BV infection since using FemiClear 
• Of those who did not report having another infection, 83% believe it was a result of using FemiClear 
• Only 9.2% reported using antibiotics since using FemiClear 
• 96.2% reported engaging in sexual activity since using FemiClear 
• 9.6% reported new sexual partners since using FemiClear 

OTC BV Treatment Conclusions

The results of the FemiClear BV testing showed a large reduction in G. vaginalis under controlled laboratory conditions. Additional testing showed the product was effective in reducing various BV symptoms in the study population. A six (6) month follow up survey showed that only 29% of respondents reported another BV infection in the six months following use of FemiClear. For the treatment of simple BV infections, FemiClear over-the-counter BV product should be considered given its ability to reduce G. vaginalis and its effectiveness in reducing the symptoms of BV. 

We’re proud to offer a new over-the-counter product for the treatment of BV infections, one that’s proven to reduce both the bacteria that causes BV and the symptoms associated with it.

Resources:

https://pubmed.ncbi.nlm.nih.gov/16652274/  

https://www.uptodate.com/contents/bacterial-vaginosis-beyond-the-basics 

¹https://emedicine.medscape.com/article/254342-overview#:~:text=BV%20is%20known%20to%20be,%2C%20Veillonella%2C%20and%20Eubacterium%20species

Claims based on clinical and/or in vitro laboratory (non-human, non-animal) studies, and traditional homeopathic practice (not accepted medical evidence; not FDA evaluated). These statements have not been evaluated by the Food and Drug Administration. This product in not intended to diagnose, treat, cure, 

*An independent accredited lab performed an in vitro (non-human/non-animal) time kill study to measure the amount Gardnerella Vaginalis that was killed. An overgrowth of Gardnerella Vaginalis, can cause a bacterial vaginosis (BV) infection, but might not be the only cause. Data on file.

**As self-reported in a comprehensive IRB approved study of >100 women. Individual results may vary. Data on file.